Merck KGaA and Pfizer Report Results of Bavencio (avelumab) in P-III JAVELIN Bladder 100 Study for Patients with Locally Advanced or Metastatic Urothelial Carcinoma

 Merck KGaA and Pfizer Report Results of Bavencio (avelumab) in P-III JAVELIN Bladder 100 Study for Patients with Locally Advanced or Metastatic Urothelial Carcinoma

Merck KGaA and Pfizer Report Results of Bavencio (avelumab) in P-III JAVELIN Bladder 100 study for Patients with Locally Advanced or Metastatic Urothelial Carcinoma

Shots:

  • The P-III JAVELIN Bladder 100 study involves assessing of Bavencio + best supportive care (BSC) vs BSC monothx in 700 patients with LA or mUC whose disease did not progress after completion of 1L Pt-chemotherapy
  • The study resulted in improvement in OS with consistent safety results and will be shared with the US FDA and multiple regulatory bodies. In 2017, the US FDA approved Bavencio under accelerated approval for LA or mUC who have disease progression during or following Pt-CT, or who have disease progression within 12 mos. of neoadjuvant or adjuvant treatment with PT-CT
  • Bavencio (avelumab) is an anti-PD-L1 Ab that blocks the interaction of PD-L1 with PD-1 receptors. In Nov 2014, Merck and Pfizer collaborated to co-develop and co-commercialize Bavencio

Click here to read full press release/ article | Ref: Pfizer | Image: Twitter

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post